cancer from whether or not to screen to the role of treatment. Given that all prostate cancer treatments carry some risk of morbidity, some men are choosing active surveillance, an approach where no definitive therapy is given (Klotz, 2007) . Herein is the appeal of preventing this disease to avoid not only the risk of prostate cancer death but also the side effects of treatment.
The heart of any preventive strategy is the identification of a high-risk group with a favorable risk benefit ratio. The well-known risk factors associated with prostate cancer are age, hereditary influences including a family history of prostate cancer, and race (Nelen, 2007) . The role of environmental influences in prostate cancer development is likely to be important as exemplified by the marked geographical difference in prostate cancer incidence. For instance, Asians, who generally have a lower incidence, develop cancer much more often when they migrate to the United States, even though the overall incidence is still lower than other racial groups (Hsing, Tsao, & Devesa, 2000) . This in turn suggests a potential dietary/lifestyle influence, and indeed, many studies have therefore investigated the role of dietary constituents in prostate carcinogenesis. The role of diet, especially a diet rich in saturated fat and red meat, has been implicated in several epidemiological studies (Dagnelie, Schuurman, Goldbohm, & Van den Brandt, 2004) , and it is reasonable to assume that A s the most common noncutaneous cancer in men, prostate cancer will be responsible for an estimated 218,890 new cases and 27,000 deaths in 2007 (Jemal et al., 2007) in the United States. Indeed, 1 in every 6 men in the United States will in their lifetime be diagnosed with prostate cancer. Prostate specific antigen (PSA) screening, which is widely prevalent in the United States and increasingly so in European countries and can detect cancers years before they would become detectable otherwise, has resulted in many prostate cancers having a long natural history (Crawford, 2003) . This coupled with the frequently advanced age at onset translates into many prostate cancer patients dying of causes other than prostate cancer. This has led to many controversies in the management of prostate Prevention of Prostate Cancer: What We Know and Where We Are Going Jayakrishnan Jayachandran, MD, and Stephen J. Freedland, MD As one of the most prevalent cancers, prostate cancer has enormous public health importance and its prevention seems to be a rational approach to attenuate the economic, emotional, physical, and social impact of this disease. This review discusses some of the options available to clinicians worldwide under the broad headings of chemoprevention and dietary modification including lifestyle issues. From the review of available literature, it is appreciated that although many exciting options such as androgen inhibitors, vitamin E, and selenium are being actively considered, they are far from being included in clinical practice. So until large randomized trials confirm the benefit of chemopreventives and dietary modifications, patients may be advised to pursue a diet and lifestyle that ensures overall fitness. Keywords: prostate cancer; chemoprevention; diet; lifestyle changes in diet may be used toward prevention. Many studies have shown evidence that suggests that invasive prostate cancer is preceded by earlier lesions such as atypical small acinar proliferation (ASAP) and prostatic inflammatory atrophy (PIA), which even antedate high-grade prostatic intraepithelial neoplasia (HGPIN; De Marzo et al., 2007; Moore et al., 2005) .
The presence of risk factors, the availability of precursor lesions, wide prevalence, and its attendant public health importance all make prostate cancer an ideal disease for primary prevention. But the challenge lies in finding effective strategies that have minimal to no adverse effects, as they have to be administered to a healthy population. Because most of the research into various interventions is in different phases of preclinical, epidemiologic, and earlyphase clinical trials, the formulation of an optimum preventive strategy for prostate cancer will take significant time and effort before any of these-either dietary modifications or chemopreventives-become standard of care. However, several agents including androgen inhibitors, vitamin E, and the mineral selenium are in large-scale phase III trials with results expected within the next few years. This article examines the myriad options under consideration for primary prevention of prostate cancer discussed under the categories chemoprevention and dietary and lifestyle modifications, with various and subcategories within these two broad categories (Table 1 ). In addition, we will review the theorized molecular mechanisms through which these agents work (Table 2 ). However, as will be evident, there is currently limited data to suggest that the risk of prostate cancer can be effectively reduced enough to be currently cost-effective when performed on an entire population.
Chemoprevention

Androgens and Androgen Inhibition
It has been suggested that androgens and androgen metabolites play a potent role in prostate cancer initiation and progression, though their exact role remains unclear (Debes & Tindall, 2002) . The frequently quoted example to highlight the presumed role of androgens on the prostate is the virtual absence of either prostate cancer or benign prostatic hyperplasia in men with congenital deficiency of 5-α-reductase type 2. This hormonal influence over prostate cancer was the rationale for the Prostate Cancer Prevention Trial (PCPT; Goodman et al., 2006) . The trial randomized more than 18,000 men over 55 with a normal digital rectal exam (DRE) and a PSA below 3 ng/ml to receive either finasteride or placebo. The rationale was that finasteride, a 5-alpha reductase inhibitor, would block the conversion of testosterone to dihydrotestosterone (DHT), the more potent androgen, and that by lowering DHT, this would help to prevent prostate cancer. The threshold for prostate biopsy was an abnormal DRE or a PSA above 4 ng/ml. The primary endpoint was the presence of prostate cancer at the end of 7 years as detected by either a biopsy during the study, that is, "for cause," or one that was mandated at the end of study, that is, end of study biopsy. The study was terminated early and results announced ahead of schedule as there was nearly a 25% reduction in prostate cancer incidence in the finasteride arm (Thompson et al., 2003) . However, the initial enthusiasm for finasteride as a chemopreventive agent was dampened by an increase in the incidence of high-grade tumors in the finasteride arm. Since, much has been discussed and written regarding the findings of the PCPT. Specifically, the increased number of high-grade tumors in the finasteride arm is of particular concern. Possible reasons ascribed to this are 1. A change in morphology induced by androgen inhibition leading to a misclassification as high grade (Bostwick, Qian, Civantos, Roehrborn, & Montironi, 2004; Reuter, 1997) . 2. The reduction in prostate volume in finasteridetreated patients might have increased sampling, and thus a biopsy, given the same number of needle cores and the same-sized tumor, would have increased the likelihood that the high-grade tumors were detected (Kulkarni et al., 2006 ). 3. PSA and DRE are more sensitive tumor markers in finasteride-treated men and thus more likely to detect higher grade disease Thompson et al., 2007) . Therefore, given that the greater prevalence of high-grade disease was only seen in the for-cause biopsies, perhaps better performance characteristics of the screening tests may have contributed to the more high-grade lesions. 4. Finally there is the possibility that the high intracellular testosterone resulting from finasteride treatment played a causal role leading to highgrade tumors (Imamov, Lopatkin, & Gustafsson, 2004) . 
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Although relatively well-tolerated, finasteride is associated with a higher incidence of sexual side effects. However, on the pro-finasteride side, there is the improvement in urinary function with reduction in both acute urinary retention episodes and progression to needing surgery for voiding difficulty.
This trial has created more questions than it has answered. First, there are concerns regarding the cost-effectiveness of adopting finasteride as a primary prevention agent (Zeliadt, Etzioni, Penson, Thompson, & Ramsey, 2005) . However, the primary concern is that finasteride may actually induce highgrade cancer, which is likely the main reason that there has been limited enthusiasm for finasteride use for the sole purpose of preventing cancer. This enthusiasm is further tempered by data from recent studies observing that among those with low testosterone, those with the lowest values were most likely to have prostate cancer on biopsy (Morgentaler & Rhoden, 2006) . Furthermore, another prospective cohort study observed that men with low testosterone levels were at increased risk of high-grade prostate cancer (Platz et al., 2006) . Therefore, if it is true that low testosterone increases the risk of highgrade cancer, then it stands to reason that raising DHT (or indirectly via testosterone supplementation) may help prevent high-grade prostate cancer (Algarte-Genin, Cussenot, & Costa, 2004). Indeed, a recent hypothesis article suggested this, though this remains a very controversial point. Given arguments for lowering androgen levels (i.e., finasteride) and for raising androgen levels (i.e., testosterone supplementation), it is clear that the exact role of androgens in prostate cancer development remains far from clear.
Despite these concerns, the role of androgen inhibitors in prostate cancer prevention remains a much discussed and researched area. Furthermore, there is another ongoing trial of 5-alpha reductase inhibition as primary prevention for prostate cancer-REDUCE (Reduction by Dutasteride of Prostate Cancer Events) in which more than 8,000 patients will be randomized to receive either dutasteride, another 5-alpha reductase inhibitor, or placebo (Andriole et al., 2004) . It will be interesting to see whether the effects of finasteride will be replicated. To conclude, it is difficult to accept androgen inhibitors as chemopreventive agents, though to date they remain one of the most promising pharmacological approaches. However, until more data are available, the role of androgen inhibitors may be confined to treatment of voiding complaints.
COX Inhibitors
The contribution of inflammatory intermediates such as eicosanoids in cancer initiation and progression is another area of interest. These intermediates might form the link between inflammation and cancer. Experimental studies have suggested that prostaglandins synthesized via the cyclooxygenase pathway play an important role in prostate cancers (Badawi, 2000) . Prostaglandins exert their tumorpromoting effects through enhanced cell proliferation, inhibition of apoptosis, and immune suppression (Hufnagl et al., 2001; Tsubouchi et al., 2000) . Studies identified that prostate cancer cells express the cyclooxygenase-2 (COX-2) enzyme at significantly higher levels than normal cells (Gupta, Srivastava, Ahmad, Bostwick, & Mukhtar, 2000) . Furthermore, COX-2 inhibitors promote apoptosis and inhibit vascular endothelial growth factor (Liu et al., 2000) . Given these preclinical observations, there is interest in using COX-2 inhibition as prevention for prostate cancer. Indeed, a meta-analysis reported a 10% lower incidence of prostate cancer among patients on aspirin (Mahmud, Franco, & Aprikian, 2004) , whereas results for other nonsteroidal anti-inflammatory drugs (NSAIDs) were less consistent. Moreover, COX-2 inhibitors have been explored in tertiary prevention with a recent phase II trial finding that treatment with celecoxib, a selective COX-2 inhibitor, resulted in prolonged PSA doubling times among men with recurrent prostate cancer (Pruthi et al., 2006) . But concern regarding the side effect profile associated with selective inhibitors is so much that an industrysponsored study on the relationship between rofecoxib and prostate cancer has now been withdrawn and more studies are required to confirm a favorable risk-benefit ratio. In the meanwhile, aspirin continues to be in active interest (Leitzmann et al., 2002) . This is reasonable, if you take into account its beneficiary role in cardiovascular disease (Bartolucci & Howard, 2006) , which is still the Number 1 killer overall and a leading killer of prostate cancer patients. However, long-term toxicity with NSAID use is of particular concern and requires further study.
Statins
Statins or hydroxy methyl glutaryl co-enzyme A (HMGCoA) reductase inhibitors are a class of lipid lowering medications that block the activity of HMGCoA reductase-the rate-limiting enzyme of cholesterol biosynthesis. They are primarily used to lower cholesterol levels in persons with or at risk of cardiovascular diseases. Like aspirin, statins are interesting from the preventive point of view, in that they are believed to have beneficial effects on both prostate cancer and the number 1 overall killer of men, namely, cardiovascular diseases. The literature on statins and prostate cancer risk has been mixed. Although a few studies did report statins were associated with a reduced prostate cancer risk (Cyrus-David, Weinberg, Thompson, & Kadmon, 2005; Shannon et al., 2005) , another study only identified a reduced risk of metastatic/fatal cancers (Platz et al., 2006) , whereas yet another study reported no overall association (Dale, Coleman, Henyan, Kluger, & White, 2006) . One very small study reported that an unfavorable lipid profile was associated with increased levels of PSA and treatment with statins lowered PSA levels, suggesting that statins can influence prostate biology (Cyrus-David et al., 2005) .
The actual means by which statins may lower prostate cancer risk is not fully understood, but the proposed mechanisms include inhibition of mavelonate CoA metabolism and thus lowering serum cholesterol levels thereby affecting cellular proliferation and migration, interfering with signal transduction of cell membrane components (lipid rafts), direct inhibition of cyclin-dependent kinases resulting in decreased cell proliferation, and direct anti-inflammatory properties of statins (Demierre, Higgins, Gruber, Hawk, & Lippman, 2005) . Although there is a lack of solid epidemiological evidence, Moyad et al. recommended statins should be the focus of the next major chemoprevention trial (Moyad, 2004) . The arguments given are persuasive, because this agent has beneficial effects on other cancers (Poynter et al., 2005) , may have synergistic activity with other chemoprevention agents (Swamy, Cooma, Reddy, & Rao, 2002) , and most important, statins diminish cardiovascular events (Cheung, Lauder, Lau, & Kumana, 2004) , which is a major killer of all people including those at risk for prostate cancer.
Selective Estrogen Receptor Modulators
It is likely that female hormones like estrogen and estradiol have a role in prostate cancer development. This is supported by the parallel rise in serum estrogen concentrations with age and the incidence of prostatic proliferative diseases both benign and malignant, which also rise with age. Diets rich in phytoestrogens are associated with a lower incidence of prostate cancer (Goetzl, Vanveldhuizen, & Thrasher, 2007) . Moreover, obesity, which is characterized by higher estrogen levels, is associated with increased risk for death from prostate cancer (Calle, Rodriguez, Walker-Thurmond, & Thun, 2003) . Selective estrogen receptor modulators (SERMs) are estrogen receptor agonistantagonists that have been associated with significant success in breast cancer chemoprevention . These agents competitively bind to estrogen receptors and thereby block estrogen-induced cellular proliferation. Experimental evidence for its activity against prostate cancer has been demonstrated in transgenic mouse models of prostate cancer (Raghow, Hooshdaran, Katiyar, & Steiner, 2002) . Phase II studies have demonstrated the safety of the SERM toremifene, and a small study even suggested that it may reduce prostate cancer prevalence in men with HGPIN (Price et al., 2006; Steiner & Pound, 2003) . This is worthy of note, because toremifene has a favorable side effect profile compared to 5-alpha reductase inhibitors.
Dietary Modification
Role of Selenium and Vitamin E
Experimental and epidemiological evidence suggests that lower levels of the trace mineral selenium may be associated with several malignancies including prostate cancer (Combs, 2005; Ip, 1998) . Although there are conflicting data, a recent meta-analysis of the observational studies has reported a potential benefit for selenium supplementation in prostate cancer (Etminan, FitzGerald, Gleave, & Chambers, 2005) . The Nutritional Prevention of Cancer Study was started, which studied the role of selenium supplementation on skin cancer as the primary endpoint. Patients were randomized to receive either 200 μg of elemental selenium supplied as a brewers yeast tablet or placebo. Although statistically nonsignificant, a higher number of skin cancers were noted in the treatment group and an overall lower incidence of several other cancers including prostate cancer as well as total cancer incidence was noted in the selenium-supplemented group (Clark et al., 1996) . The anticancer effects of selenium can occur through multiple mechanisms, but it is thought to be mediated mostly through the active selenium metabolite, methyl selenol (Ip, 1998) . A few of the proposed mechanisms include:
In addition to selenium, there has been much interest in vitamin E or its ubiquitous natural form, α tocopherol. Observational studies on vitamin E and prostate cancer risk have expressed divergent views about the protective effects of vitamin E on prostate cancer incidence (Schuurman, Goldbohm, Brants, & van den Brandt, 2002; Willett et al., 1984) . However, all these studies have the limitations of relying on data from dietary questionnaire and thus potentially suffer from recall bias and poor correlation of dietary intake with plasma values. Therefore, the stronger data to link vitamin E and prostate cancer risk come from randomized controlled trials. Specifically, interest in vitamin E was rekindled based on the Alpha Tocopherol Beta Carotene Study (ATBC). This study included 29,133 Finnish men who smoked >5 cigarettes a day and were randomized to vitamin E and/or β-carotene or placebo to assess whether these agents could prevent lung cancer. Although the βcarotene arm was stopped early due to an increased risk of lung cancer, secondary analysis reported a 32% reduction in the risk of prostate cancer among men on the vitamin E arm (Albanes et al., 1995) . Although the exact mechanism through which vitamin E operates is not known, there are several potential mechanisms:
1. Vitamin E possesses significant antioxidant activity by which it protects cell membranes from free radical-induced damage thereby reducing carcinogenic potential (Ottino & Duncan, 1997) . 2. Inhibition of prostaglandin and arachidonic acid metabolism reducing inflammatory intermediates, which may play a role in the interplay of chronic inflammation and carcinogenesis (Traber & Packer, 1995) . 3. Inhibition of protein kinase C, which appears to be independent of the antioxidant activity and is theorized to reduce cellular proliferation (Ottino & Duncan, 1997 ). 4. Induction of apoptosis (Shiau et al., 2006) . 5. Interaction with the enzymes involved in cholesterol biosynthesis can lead to decreased levels of steroid hormones, especially androgens. This may form the basis of its activity in prostate cancer (Barella, Rota, Stocklin, & Rimbach, 2004) .
Excitement for the above two agents in prostate cancer prevention is diminished when these studies are examined in detail. It must be noted that the risk reduction effects of selenium were noted only in the lower tertiles, which makes us surmise that supplementation is effective only for those individuals with deficiency (Duffield-Lillico et al., 2003) . Coupled with the understanding that selenium may be a prooxidant in higher concentrations (Drake, 2006) , more data are required before we accept these supplements as a standard practice. Moreover, recent data suggest that only men with the AA genotype of superoxide dismutase-the principal antioxidant enzyme in mitochondria-may derive benefit from selenium supplementation when compared to VV/VA phenotype (Li et al., 2005) . Therefore, genetic predisposition may determine the effectiveness of selenium-mediated risk reduction. There is also concern regarding the increased risk of Type 2 diabetes mellitus in patients on long-term selenium supplementation based on recent data from the Nutritional Prevention of Cancer Study (Stranges et al., 2007) . In the case of vitamin E, it must be noted that all the participants in the ATBC trial were smokers and it would be difficult to extrapolate the same findings to nonsmokers. In fact, this observation has been reinforced by data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial in which the association between increased vitamin E intake and lower prostate cancer risk was only seen among smokers (Kirsh et al., 2006) . Similar observations were noted in the U.S. Health Professionals Follow-up Study (Chan et al., 1999) . Finally, until more data are accumulated, caution must be exercised prior to beginning supplementation because of the fact that supplements may have untoward effects on organs other than the prostate. For example, vitamin E can also increase the risk of hemorrhage especially when combined with anticoagulants (Leppala et al., 2000) . More important, a recent meta-analysis concluded that vitamin E supplementation may actually increase overall mortality by 4%, which would more than offset a reduction in prostate cancer deaths, which only account for 3% of all deaths in men (Bjelakovic, Nikolova, Gluud, Simonetti, & Gluud, 2007) .
Many of these concerns will hopefully be answered by the currently running Selenium and Vitamin E Cancer Prevention Trial (SELECT) that will study the effect of both selenium and vitamin E with prostate cancer as the primary endpoint. This study conducted by the Southwest Oncology Group proposes to enroll more than 32,000 men to be randomized to receive selenium and/or vitamin E versus placebo in a 2 × 2 study design (Klein, 2004) . This will include Caucasians over 60 years of age and African Americans over 55 years with a normal DRE and a PSA less than 4 ng/ml. The incidence of prostate cancer as determined by annual rectal exams and PSA values will be the primary endpoint. The study proposes to examine the incidence and mortality statistics of other cancers and diseases as secondary endpoints. Results from this study, which are expected in 2013, are eagerly awaited.
Soy and Phytoestrogens
A significantly lower incidence of prostate cancer is noticed in men in Asia. The higher intake of soy products rich in isoflavinoids, such as genistein and daidzein, and their higher levels in plasma (Adlercreutz, Markkanen, & Watanabe, 1993) and prostatic fluids suggest that they may be involved in the lower prostate cancer incidence. Experimental evidence also supports this view (Wang, Eltoum, & Lamartiniere, 2007) . Isoflavinoids primarily exert their action through the estrogen receptor (both α and β) thereby inhibiting cellular proliferation (Goetzl et al., 2007) . Other proposed mechanisms include inhibition of cell signaling pathways (Davis, Singh, Bhuiyan, & Sarkar, 1998) , promotion of apoptosis (Raffoul et al., 2006) , and inhibition of angiogenesis (Guo, Wang, Hoot, & Clinton, 2007) . These products have additional advantageous effects in cardiovascular diseases and osteoporosis (Branca, 2003; Clarkson, 2002) . There are no reports of any serious toxicity at least with short-term use. Future studies are needed to assess the role of these agents for both prostate cancer prevention and promotion of overall health.
Green Tea
Another proposed reason for the low incidence of prostate cancer in Asians is high dietary intake of green tea (Jian, Xie, Lee, & Binns, 2004) . The active principle responsible for anticancer effects is thought to be catechins, which act through multiple sites including cell cycle regulation and apoptosis, decreasing ornithine decarboxylase activity, inhibition of proteasome activity, and inhibition of matrix metalloproteases (Adhami, Ahmad, & Mukhtar, 2003) . Specifically, epigallocatechin 3 gallate has been identified to have significant chemopreventive action in experimental models (Adhami et al., 2003) . Although there have been no known adverse effects for this natural product at the doses consumed in epidemiological studies, the status of this agent in the preventive armamentarium is unclear for now.
Lycopene
Tomatoes and the principal carotenoid present in them, lycopene, have demonstrated activity against prostate cancer as evidenced by several tissue culture and epidemiological studies. In their study of more than 50,000 men from the Health Professionals Follow-up Study, Giovanucci et al. noticed a reduction in prostate cancer risk among men with higher lycopene intake (Giovannucci, Rimm, Liu, Stampfer, & Willett, 2002) . They reported a stronger benefit for cooked or processed tomatoes, which have higher lycopene bioavailability. Apart from its antioxidant action, lycopene exerts its effect on prostate carcinogenesis through insulin-like growth factor 1, induction of apoptosis, and increased synthesis of connexins, which are involved in gap junction communication (Barber et al., 2006) . However, not all epidemiological studies have shown consistent findings. For example, a multiethnic case control study conducted in the United States and Canada found no consistent association between either tomato or lycopene intake and prostate cancer risk (Kolonel et al., 2000) . Overall, though some conflicting data exist, the data seem to suggest that lycopene/tomatoes might be beneficial for prostate cancer prevention. Being a vegetable carotenoid, lycopene is likely to be safe for prolonged administration at moderate to low doses. But much more evidence is needed before supplementation above and beyond a general increased intake of fruits and vegetables in the diet can be recommended. Recently, an animal study by Boileau et al. noted a statistically significant reduction in prostate cancer growth in rats and mice fed with tomato powder, whereas treatment with synthetic lycopene supplementation had no effect (Boileau et al., 2003) . This brings to question the wisdom of choosing single compounds over a combination of phytochemicals that is present in whole foods. Interestingly, the same study noted a reduction in prostate cancer risk with calorie restriction. These observations serve as a pointer to the notion that a reductionist approach to prostate cancer prevention may not be the answer. In fact, the preventive strategy will be better served by an approach that looks at a more complete perspective with changes in both diet and lifestyle.
Lifestyle
Most studies report either positive or no association between prostate cancer risk and obesity (Cerhan et al., 1997; Schuurman, Goldbohm, Dorant, & van den Brandt, 2000; Veierod, Laake, & Thelle, 1997) , and more recent studies actually suggest obese men are less likely to be diagnosed with prostate cancer (Gong et al., 2006; Rodriguez et al., 2007; Wright et al., 2007) . However, there is increasing evidence to link obesity with high-grade disease (Gong et al., 2006) or fatal prostate cancer (Andersson et al., 1997; Calle et al., 2003; Rodriguez et al., 2001; Wright et al., 2007) . Keeping this in mind, coupled with the fact that obesity is linked to other cancers as well as multiple medical problems such heart disease, diabetes, and hypertension, it is clearly pragmatic to advise patients to achieve and maintain a normal weight. Moreover, given that most people are overweight or obese, to become normal weight requires weight loss. To lose weight, patients must consume fewer calories than their bodies demand. This can be accomplished via either caloric restriction or increased physical activity. Indeed, caloric restriction has been associated with delayed prostate tumor growth in multiple animal models (Kritchevsky, 2002; Pugh, Oberley, & Weindruch, 1999) . In addition, weight loss, which essentially signifies a negative energy balance, has been associated with a reduced risk of high-grade prostate cancer (Rodriguez et al., 2007) and weight gain or positive energy balance has been associated with increased risk of advanced/fatal prostate cancer (Wright et al., 2007) .
Restriction of fat intake can be considered as another approach, because fat intake has been positively linked to prostate cancer risk by some studies (Demark-Wahnefried et al., 2001; Gann et al., 1994) . However, fat restriction often comes at the price of increased intake of simple carbohydrates, which have been linked with prostate cancer risk (Bidoli et al., 2005) . Therefore, the most prudent method would be to restrict saturated fat and simple carbohydrates and ideally total calorie intakecaloric restriction.
Even though the influence of physical activity on prostate cancer risk is contentious-some studies show an inverse association (Giovannucci, Liu, Leitzmann, Stampfer, & Willett, 2005) while others report no association (Patel et al., 2005) and one study identifies a positive association (Cerhan et al., 1997 )-its benefit on overall cardiovascular health is well established with improvement in lean body mass, insulin sensitivity, reduction of abdominal obesity, and a lower blood pressure.
From the discussion above on antioxidants and plant products, it is clear that the inclusion of a diverse diet rich in vegetables, vitamins, and trace minerals along with lower consumption of refined carbohydrates and fat, especially saturated fat, can lead to not only a healthier prostate but to a better cardiovascular profile. Much more impact would be made on the health of people at risk of developing prostate cancer and the general population by adopting lifestyle practices that are proven to be healthy rather than just focusing on prostate cancer-specific approaches.
Conclusion
The prospect of preventing prostate cancer has enormous public health implications. We are far from formulating a preventive strategy that can be accepted in the realm of standard practice. It is clear that many of the options available are from natural dietary sources. Currently available data suggest that most agents touted as pharmacological chemopreventives have profiles that would not be ideal for administration in the general population or even in a high-risk population. Most preventive approaches have focused on dietary supplements or pharmacological agents-a "pill." For example, phase III clinical trials are currently under way to assess the role of vitamin E and selenium, and the results of this study may well change the paradigm for prostate cancer prevention. Therefore, until such large randomized studies can show benefit for such an approach, it would be pragmatic to follow dietary and lifestyle practices that promote overall health, which in turn may also help prostate cancer prevention.
